The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
After a median follow-up of 42.5 months, zanubrutinib resulted in a sustained progression-free survival (PFS) benefit compared with ibrutinib, with responses deepening over
The US Food and Drug Administration (FDA) granted Orphan Drug designation to MB-105, a CD5-targeted chimeric antigen receptor (CAR)-T cell therapy, for the
Differences in the bone marrow microenvironment may determine why some relapsed acute myeloid leukemia (AML) patients respond better to donor lymphocyte infusion (DLI)
A study found that “pacritinib may offer a unique survival advantage” for patients with myelofibrosis (MF) and thrombocytopenia who achieve any spleen volume
Results of the CARTITUDE-4 trial assessing patient-reported outcomes in those with multiple myeloma receiving the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel
The IRAK-4 inhibitor emavusertib showed encouraging clinical activity in patients with higher-risk myelodysplastic syndromes (MDS), according to preliminary data from the phase 1/2
The largest study to date evaluating the impact of circulating lymphoma cells (CL) on outcomes in patients with newly diagnosed de novo diffuse
he US Food and Drug Administration (FDA) has granted orphan drug designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the
Dr. Jabbour discusses obecabtagene autoleucel (obe-cel), an autologous CD19-directed chimeric antigen receptor (CAR)-T cell therapy, in relapsed or refractory adult B-cell acute lymphoblastic
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for imetelstat in the treatment
